CHD Chemicals (539800)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹6.49 |
| Market Cap | ₹6.56 Cr |
| P/E Ratio | 0 |
| ROCE | 0.25% |
| ROE | -1.44% |
| Dividend Yield | 0% |
| Profit Growth | -150% |
| Debt/Equity | — |
| Sales Growth | -29.41% |
| 52-Week Range | ₹4.11 — ₹7.24 |
| Sector | Chemicals & Petrochemicals |
| Book Value | ₹12.9 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹6.49, CHD Chemicals sells at half its book value of ₹12.90. That sounds like a classic Graham bargain. But let me stop there. This is a trading business in chemicals with a market cap of just ₹7 crore. While the price-to-book of 0.50 gives me a margin of safety on paper, the underlying economics are poor. Return on equity is -1.44% and ROCE is a bare 0.25%. The company is not earning a decent return on its assets. Sales have shrunk by 29.41%, and profit growth has fallen by 150% — meaning it is now loss-making. The latest quarter shows sales of ₹1 crore and a net profit of zero (or less). The Piotroski F-score of 3 out of 9 reinforces my worry: financial health is weak. There is no dividend, and promoter holding is not disclosed — a red flag for minority shareholders. The P/E is meaningless when earnings are absent. So what do I actually own? A small trading company with ₹12.90 of book value per share, but that book value may erode if losses continue. I cannot call this a great business. It is a possible asset play, if the assets are real and can be freed up. But I need evidence: a return to sales growth, positive net income, and a clear signal that management will create value for shareholders. Without those, a cheap stock can stay cheap — and often gets cheaper. I will only invest a tiny speculative sum, if at all, and I will watch the balance sheet, not the price chart.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer